7th Annual PREDiCT: Tumor Models Boston

Memo

The 7th Annual PREDiCT: Tumor Models Boston summit will explore robust preclinical strategies utilizing current and emerging model systems to overcome core challenges across the early stages of cancer drug development. Presentations will span preclinical strategies validating new anticancer drugs, assessing therapeutic index and identifying surrogate markers of tumor progression.Plug into a network of preclinical and translational scientists seeking to share methods for the rational design of combinations, patient stratification and identify new strategies to model metastasis, resistance and sensitivity.URLs:Tickets: https://go.evvnt.com/392712-1?pid=5569Brochure: https://go.evvnt.com/392712-2?pid=5569PriceConference only - Drug Developers: USD 2299.0Conference only - Academics: USD 1499.0Artists / Speakers: Alejandro Amador, Head, Scientific Leader Discovery Biology Automation, GSK, Ana Zarubica, COO, Inserm Centre D’Immunoph- ENomique, Andrew Rhim, Associate Director - Translational Research & Assistant Professor – Gastroenterology, MD Anderson Cancer Center, Chen Zhao, Clinical Fellow, National Institutes of Health, Corinne Reimer, Associate Director In Vivo Pharmacology, AstraZeneca, Dan Powell, Director Clinical Tumor Tissue Facility & Associate Professor, University of Pennsylvania, Davy Ouyang, Executive Director, Crown Bioscience, Enrique Alvarez, Director - Preclinical Development, Kleo Pharmaceuticals Inc., Esmaiel Jabbari, Professor, University of South Carolina, Fangxian Sun, Lead Investigator - Research Pharmacology, Sanofi, Fred Roberts, Sales Manager, Fuji film Visual Sonics, Geeta Sharma, Scientific Fellow, Translational Research, Tesaro, Hervé Luche, Scientific Director Immunophenotyping Unit, Inserm Centre D’Immunoph- ENomique, Hongmin Chen, Principal Scientist, Merck, Jenni Bernoulli, COO, Pharmatest Services, Juan Delgado, Lead Data Scientist, Fuel3D, Keiji Furuuchi, Associate Director & Head of Immunotherapy & Preclinical Development, Eisai, Kerry Whalen, Director - Discovery & Translational Biology, Tarveda Therapeutics, Lindsey Crowley, Scientist EMD, Serono, Maryland Franklin, Vice President – Scientific Development, MI Bioresearch, Mike Brehm, Professor, University of Massachusettes, Mithun Khattar, Scientist & Immuno- Oncology Lead, Takeda, Neil Michaud, Associate Director - Translational Medicine, EpiZyme, Omid Ghasemi, Scientist I, Imaging, Takeda, Rhys Jones, Senior Director DMPK, Pfizer, Rick Huntress, Director of Commercial Business Development, The Jackson Laboratory, Sarah Knutsen, Director, Preclinical Biology, Twentyeight-Seven Therapeutics, Shanthi Ganesh, Associate Director, Dicerna Pharmaceuticals Corp., Shiva Kazerounian, Principal Scientist, In Vivo Pharmacology Lead, Berg Pharma, Shuxi Qiao, Senior Scientist Internal Medicine Research Unit, Pfizer Inc., Silvia Goldoni, Investigator & Head of Oncology Lab, Novartis, Srinivas Rao, Global Head of Translational In Vivo Models & Research Platform, Sanofi, Stefan Jellbauer, Technical Liaison for Translational Applications, Mitra Biotech, Tseten Jamling, VP of Research and Development, Hera Biolabs, Yvonne Evrard, Operations Manager, National Institute of Health SciencesTuesday July 16, 2019 at 7:30 am (ends Thursday July 18, 2019 at 5:00 pm)Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston 02116, United States